
Oct 7, 2026 · 44 min
Cramer tests consumer resilience, AI defenses and Wall Street targets
Mad Money w/ Jim Cramer 10/7/26
The episode connects stock-specific questions to broader debates about spending, data-center investment, software durability and the usefulness of analyst forecasts.
- 1Levi Strauss presents resilient apparel demand despite mixed results, while Constellation Brands argues its beer portfolio can recover.
- 2Veeva’s CEO says specialized, confidential life-sciences software offers protections generic AI tools cannot easily replicate.
- 3Cramer questions whether Wall Street price targets help investors, especially when analysts revise them after stocks fall.
Don't miss
Peter Gassner makes the case that Veeva’s reliability and confidentiality requirements protect specialized life-sciences software from generic AI disruption.
The brief
Jim Cramer opens with market conditions and corporate credit, including SpaceX’s reported effort to borrow $40 billion for NVIDIA chips and data-center capacity.
Viewer questions on Western Digital, Vertiv and Chipotle widen into a debate over valuation, data-center infrastructure and whether inflation-driven pressure on restaurants will pass.
Levi Strauss reports mixed but encouraging results, while its discussion of wholesale, direct sales, China and Beyond Yoga points to resilient apparel demand.
Veeva CEO Peter Gassner argues that clinical-trial reliability and confidentiality give specialized life-sciences software an edge over generic AI tools.
The episode closes by challenging Wall Street price targets, particularly when analysts raise them after a stock declines and investors may mistake revision for insight.
What was said on this episode
47 statements · 36 positive · 5 negative · 4 mixed · 2 neutral
A stronger Treasury auction would likely have improved the stock market session.
“Now, if the auction had gone better, we probably would have had a much better day.”
Listen at 1:34
Greater difficulty owning stocks pushes money to the sidelines.
“Anything that makes stocks tougher to own will push money onto the sidelines”
Listen at 1:51
Most S&P 500 companies face credit costs, unlike favored AI companies.
“Now we have two classes of companies in this country. We have old-school companies that need credit and suddenly find it hard to get, all the while paying more for it if the auctions go sour. And that's the vast majority of the S&P 500. And then we have another group of companies. I call them sainted companies, companies that even though they might need credit, definitely don't need to pay the going rate.”
Listen at 2:38
AI companies appear able to borrow more easily than other companies.
“They seem to be able to borrow at their leisure.”
Listen at 3:01
SpaceX has a triple-B credit rating.
“SpaceX is rated at triple B.”
Listen at 3:29
SpaceX likely borrows at relatively low spreads over Treasury rates.
“I bet the SpaceX, more on them later, doesn't have to pay that much over treasuries”
Listen at 3:42
Several AI-related sectors are largely insulated from current credit concerns.
“data centers, semiconductors that make AI possible, power companies and cybersecurity that basically have nothing to do with these credit concerns.”
Listen at 4:49
Most AI data-center stocks are unrelated to federal borrowing costs.
“The AI data center stocks, maybe aside from Oracle, have nothing to do with what price the federal government borrows at.”
Listen at 5:51
Micron is substantially cheaper than Western Digital.
“Micron is much cheaper.”
Listen at 6:46
Micron is cheaper than Western Digital and could rise substantially.
“Micron is much cheaper. We know Micron really well here. We like it a lot. We think it can go much higher.”
Listen at 6:46
Micron’s stock can rise substantially.
“We think it can go much higher.”
Listen at 6:50
Western Digital is inferior to Micron as an investment.
“Western Digital is not as good as Micron.”
Listen at 7:02
Vertiv is a good company with a strong order book.
“I think Vertiv is a good company. I think they've got a great order book.”
Listen at 7:18
Cramer recommends buying Vertiv after a decline.
“I'd like to buy it when it's down.”
Listen at 7:26
Levi Strauss Europe direct-to-consumer business has rebounded into positive growth.
“the business rebounded. So it's positive now, quarter to date.”
Listen at 11:37
Levi Strauss China sales rose 13% this quarter and performed well year-to-date.
“China was up 13 percent this quarter and it has been doing well all year.”
Listen at 13:18
Beyond Yoga is making strong progress.
“the Beyond Yoga team is making great progress.”
Listen at 14:50
Levi Strauss consumers remain resilient despite tighter conditions.
“our consumer continues to prove resilient.”
Listen at 15:56
Levi Strauss stock will rebound similarly after improving results.
“I think the same thing is going to happen here with Levi Strauss”
Listen at 17:39
Constellation Brands reported a better-than-feared quarter.
“Constellation actually reported a much better than feared quarter.”
Listen at 20:11
Constellation Brands trades at slightly above ten times estimated annual earnings.
“With the stock still trading just over 10 times this year's earnings estimate”
Listen at 24:28
Cramer’s view of Constellation Brands stock has improved materially.
“I feel much better about this stock than I did 24 hours ago.”
Listen at 25:06
Current pressures on restaurant stocks will eventually pass.
“Me, I think this too shall pass”
Listen at 25:57
Restaurant-sector weakness from inflation and gasoline costs will eventually pass.
“I think this too shall pass”
Listen at 25:58
Cramer considers $30 a favorable buying level for Chipotle.
“Probably very one of the few people who thinks that $30 is a good level to buy CMG.”
Listen at 26:02
Veeva’s clinical-trial software business is difficult to disrupt.
“This was never going to be an easy business to disrupt.”
Listen at 27:10
Claude and Gemini cannot replace specialized clinical-trial applications.
“You're not going to do that with Claude or Gemini.”
Listen at 28:26
Clinical trials can have life-or-death consequences for patients.
“a clinical trial is a serious thing. It can be a life or death thing.”
Listen at 28:56
Veeva Falcon agents can automate some repetitive life-sciences work.
“we have Falcon agents that can do some of the repetitive work in life sciences”
Listen at 30:41
Accelerating biology will produce more medicines that cure more diseases.
“the actual core biology is accelerating. So you're going to have more medicines curing more diseases.”
Listen at 31:15
Accelerating biology will produce more medicines curing more diseases.
“you're going to have more medicines curing more diseases”
Listen at 31:19
Veeva Systems targets $6 billion in revenue and says it is on track.
“$6 billion revenue. Yes, that's our goal. And yes, we're on track.”
Listen at 32:13
Veeva Basics has nearly 200 customers and is highly affordable.
“We have almost 200 customers on Viva Basics. It's super affordable.”
Listen at 32:46
Cramer favors Medtronic but disfavors MiniMed.
“I do like Medtronic, but I do not like Minimet.”
Listen at 34:37
Cramer sees no reason to buy RMDS.
“I see no reason to buy it.”
Listen at 35:02
Cramer has a favorable view of L3Harris.
“I kind of like L3 Harris”
Listen at 35:39
Cramer recommends accumulating L3Harris in staged purchases.
“you want to buy 100 shares by 25 here”
Listen at 36:03
“Buy your first to 23, and then you buy it down to 20.”
Listen at 36:11
GigaCloud Technology is extremely speculative but suitable for speculation.
“This is one of the most speculative stocks on earth. If you want speculation, I say Giga Cloud.”
Listen at 36:43
Cramer believes Archer Daniels Midland is entering a favorable period.
“I think Archer Daniels' time has come.”
Listen at 38:18
Babcock is a reasonable small speculation, but investors should limit position size.
“It's a pretty good spec of five bucks. Don't put too much money into it. But I think it's a nice speculation.”
Listen at 38:59
Cramer considers Babcock a worthwhile speculative investment.
“I think it's a nice speculation.”
Listen at 39:03
Rising analyst targets amid a post-earnings decline may signal excessive selling.
“When you see a stock go down after it reports, but analysts raise their price targets en masse, that's a sign this stock probably shouldn't be going down at all.”
Listen at 39:54
Cramer uses divergence between analyst targets and stock performance to identify entries.
“when I'm looking for an entry point in a stock I like, I always measure the disparity between analyst coverage and that stock's performance.”
Listen at 40:24
SpaceX could become Nvidia’s largest customer if chip purchases continue.
“SpaceX could end up being NVIDIA's largest client at this pace.”
Listen at 43:02
SpaceX may reach a major public-market milestone sooner than Tesla did.
“it's becoming more and more likely that SpaceX could come to fruition a lot earlier than Tesla ever did.”
Listen at 43:12
SpaceX could achieve major success sooner than Tesla did.
“SpaceX could come to fruition a lot earlier than Tesla ever did.”
Listen at 43:14
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.